Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jul 2, 2018- Company invests €66 million in Chengdu, Sichuan province, China
-
Jun 25, 2018- Toujeo (insulin glargine injection 300 Units/mL) met primary endpoint in lowering blood sugar levels and was non-inferior to insulin degludec in adults with type 2 diabetes not previously on insulin
-
Jun 4, 2018-- Patients treated with cemiplimab experienced robust anti-tumor effects
-
May 21, 2018* In steroid-sparing VENTURE trial, Dupixent-treated patients substantially reduced use of oral corticosteroids, yet had fewer exacerbations and improved lung function compared to placebo.
-
May 16, 2018* U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018
-
May 1, 2018-- Agreement provides Praluent at lower net price and enables streamlined patient access based on physician attestation
-
Apr 25, 2018- If approved, health care professionals will be able to use the same 0.5 mL dose of Fluzone Quadrivalent vaccine with all patients ages 6 months and older for whom flu vaccination is recommended - which may provide more flexibility and convenience to immunizers.
-
Mar 27, 2018* Max SoloStar holds more insulin than any other long-acting insulin pen
-
Mar 27, 2018- Sanofi teams up with television personality Adam Savage and allergist Dr. Neeta Ogden to help dispel common allergy misconceptions with facts
-
Mar 10, 2018* Precision medicine approach will focus efforts on high-risk patients, such as those who have had heart attacks or unstable angina and cannot reduce their LDL-C below 100 mg/dL despite maximally-tolerated statins
-
Mar 10, 2018* ODYSSEY OUTCOMES trial met its primary endpoint, demonstrating that high-risk patients who added Praluent® (alirocumab) Injection to maximally-tolerated statins experienced significantly fewer major adverse cardiovascular events compared to those on maximally-tolerated statins alone
-
Jan 8, 2018Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma
-
Dec 13, 2017High and durable response rate in disease without any FDA-approved therapies
-
Dec 11, 2017* First FDA-approved follow-on mealtime insulin
-
Dec 7, 2017Phase 3 trials will evaluate isatuximab, an anti-CD38 antibody, in combination with other cancer treatments
-
Dec 4, 2017First head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo (insulin glargine 300 Units/mL) versus insulin degludec
-
Nov 30, 2017Two large real-world analyses compared adults with type 2 diabetes who were switched to Toujeo (insulin glargine injection 300 Units/mL) to those switched to insulin degludec